Expand universal mismatch repair immunohistochemistry testing for all brain & small bowel tumors?

Catie Neumann – CGA-IGC Research Committee

Mismatch repair (MMR) immunohistochemistry (IHC) has historically been utilized to screen for Lynch syndrome in colorectal and endometrial tumors. When the immunotherapy Pembrolizumab became FDA-approved for treatment in multiple cancer types showing MMR deficiency, the spectrum of tumors identified with MMR deficiency expanded.